Takeda today announced its U.S. Business Unit will further expand its patient assistance program to help more patients access their medications.

Data show the prescription drug Entyvio, which is used to treat irritable bowel disease, is as effective as lab-controlled studies suggested before its United States release in 2014

Takeda Pharmaceuticals U.S.A. Inc. and Cognition Kit Limited are partnering to pilot an app for the Apple Watch to monitor and assess cognitive function in patients with major depressive disorder (MDD).

Exemplifying criteria for non-discrimination, benefits coverage and overall diversity awareness for LGBT employees, Takeda Pharmaceuticals recently took the top spot in the Human Rights Campaign Foundation’s 2017 Corporate Equality Index.

Leaders and officials with Takeda Pharmaceutical Company Limited recently highlighted their sustained commitment to fighting Hodgkin lymphoma at the 10th International Symposium on Hodgkin Lymphoma (ISHL) in Germany.

Takeda Pharmaceutical Company Limited and Ultragenyx Pharmaceutical Inc., a company that develops products for rare and ultra-rare diseases, recently announced a strategic partnership for developing and commercializing therapies.

Takeda Pharmaceutical Company Limited recently announced that it has received a significant grant from the Bill & Melinda Gates Foundation to support Takeda’s ongoing polio eradication efforts, which are taking place in developing countries.

Takeda Pharmaceutical Company Limited and Theravance Biopharma Inc. recently entered a global license, development and commercialization agreement for TD-8954, a potential treatment for gastrointestinal motility disorders like enteral feeding intolerance (EFI).

Takeda Pharmaceutical Company Limited recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted Adcetris a positive review.

Officials are Takeda Pharmaceutical Company Limited recently released the results from its randomized, international, placebo-controlled, double-blind, phase-three trial for Ninlaro, the first oral proteasome inhibitor.

Takeda Pharmaceutical Company Limited and H Lundbeck A/S recently stated that the U.S. Food and Drug Administration has issued a complete response letter concerning Brintellix and its supplemental new drug application.

Takeda Pharmaceutical Company Limited recently announced that the interim findings from its GEMINI Long-Term Safety study have shown positive results among clients with moderately to severely active ulcerative colitis.

Japanese companies Takeda Pharmaceutical Co. Limited and Otsuka Pharmaceutical Co. Ltd. have received New Drug Application approval from the Ministry of Health, Labor and Welfare for Vonosap pack 400, Vonosap pack 800 and Vonopion.

Japanese patients living with blood and bone marrow cancer, or multiple myeloma, may soon have another option for treatment with the Japanese Ministry of Health, Labor and Welfare's approval of ixazomib, a product of Takeda Pharmaceutical Co. Ltd., as an Orphan Drug.

Enrollment has concluded for a Phase III trial of the genetic-based biomarker risk assignment algorithm (BRAA), which will assess the safety and effectiveness of investigational therapy pioglitazone 0.8 mg SR.

The FDA Psychopharmacologic Drugs Advisory Committee (PDAC) recently found Brintellix to be effective for the treatment of some cognitive function problems in adult patients living with major depressive disorder (MDD) by an 8-2 vote.

Japanese pharmaceutical companies Mersana Therapeutics and Takeda Pharmaceutical Co. are collaborating on a project through which Takeda will gain rights to anti-tumor drug XMT-1522 outside the U.S. and Canada.

The European Commission has approved a Type II variation on the labels of Adcetris (brentuximab vedotin). The new labels will include re-treatment data for adult patients who have relapsed after initially successful treatment with Adcetris.

Ninlaro (ixazomib), a product of Japanese pharmaceutical company Takeda, has received approval from the U.S. FDA. Ninlaro is a capsule taken once a week. It is indicated for use in the treatment of multiple myeloma patients who have tried at least one other therapy.

Japan-based Takeda Pharmaceutical Co. and U.S.-based Cour Pharmaceutical Development Co. are working together to study and develop new therapies for patients living with celiac disease. Celiac disease is an autoimmune disorder that affects the small intestine.